CY1119295T1 - Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης - Google Patents
Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσηςInfo
- Publication number
- CY1119295T1 CY1119295T1 CY20171100836T CY171100836T CY1119295T1 CY 1119295 T1 CY1119295 T1 CY 1119295T1 CY 20171100836 T CY20171100836 T CY 20171100836T CY 171100836 T CY171100836 T CY 171100836T CY 1119295 T1 CY1119295 T1 CY 1119295T1
- Authority
- CY
- Cyprus
- Prior art keywords
- subject
- transgene
- brain
- storage diseases
- lysosomic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Αυτή η περιγραφή παρέχει μεθόδους και συνθέσεις για την θεραπεία ασθενειών λυσοσωμικής αποθήκευσης σε ένα υποκείμενο. Σε μία άποψη της εφεύρεσης, ένα διαγονιδιακό προϊόν χορηγείται σε ένα υποκείμενο με την χορήγηση ενός ανασυνδυασμένου νευροτροφικού ιικού φορέα που περιέχει το διαγονίδιο στον εγκέφαλο. Ο ιικός φορέας παραδίδει το διαγονίδιο σε μια περιοχή του εγκεφάλου που είναι ευάλωτη σε μόλυνση από τον ιό και η οποία εκφράζει το κωδικοποιημένο προϊόν ανασυνδυασμένου ιικού γονιδίου. Παρέχονται επίσης συνθέσεις για την παράδοση ενός διαγονιδιακού προϊόντος σε ένα υποκείμενο με την χορήγηση ενός ανασυνδυασμένου νευροτροφικού ιικού φορέα που περιέχει το διαγονίδιο στον εγκέφαλο του υποκειμένου. Το διαγονιδιακό προϊόν μπορεί να είναι οποιοδήποτε που είναι ανεπαρκές σε μία ασθένεια λυσοσωμικής αποθήκευσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92494707P | 2007-06-06 | 2007-06-06 | |
PCT/US2008/065481 WO2008154198A1 (en) | 2007-06-06 | 2008-06-02 | Gene therapy for lysosomal storage diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119295T1 true CY1119295T1 (el) | 2018-02-14 |
Family
ID=40130114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100836T CY1119295T1 (el) | 2007-06-06 | 2017-08-03 | Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης |
Country Status (14)
Country | Link |
---|---|
US (2) | US8796236B2 (el) |
EP (2) | EP3252161B1 (el) |
AR (1) | AR070000A1 (el) |
CY (1) | CY1119295T1 (el) |
DK (1) | DK2158322T3 (el) |
ES (2) | ES2635726T3 (el) |
HR (1) | HRP20171165T1 (el) |
HU (1) | HUE035779T2 (el) |
IL (3) | IL202522A (el) |
LT (1) | LT2158322T (el) |
PL (2) | PL3252161T3 (el) |
PT (2) | PT3252161T (el) |
SI (1) | SI2158322T1 (el) |
WO (1) | WO2008154198A1 (el) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
PL1988823T3 (pl) | 2006-02-09 | 2019-01-31 | Genzyme Corporation | Powolne dostarczanie dokomorowe |
SI2158322T1 (sl) | 2007-06-06 | 2017-10-30 | Genzyme Corporation | Genska terapija za bolezni lizosomskega shranjevanja |
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
US8242086B2 (en) * | 2008-11-12 | 2012-08-14 | Duke University | Methods and compositions for treating disorders caused by a deficiency in a gene product of a CLN gene |
PT2424571T (pt) | 2009-04-30 | 2020-05-06 | Ospedale San Raffaele Srl | Vetor génico |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
CA2833905C (en) | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
CA3066596A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
CA2832151C (en) | 2011-03-31 | 2021-06-15 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
WO2012145646A1 (en) * | 2011-04-20 | 2012-10-26 | Miguel Sena-Esteves | Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis |
US20130039888A1 (en) | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
EP2751279B1 (en) | 2011-08-31 | 2017-10-04 | St. Jude Children's Research Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
CA2912678C (en) * | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
WO2015031686A1 (en) | 2013-08-30 | 2015-03-05 | Amgen Inc. | High titer recombinant aav vector production in adherent and suspension cells |
RU2738421C2 (ru) | 2014-10-21 | 2020-12-14 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
RU2020109343A (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
CA3019315A1 (en) * | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
CA3008268A1 (en) * | 2015-12-15 | 2017-06-22 | Genzyme Corporation | Adeno-associated viral vectors for treating mucolipidosis type ii |
CN109069671B (zh) * | 2016-01-19 | 2022-10-18 | 加利福尼亚大学董事会 | Danon病和其它自噬障碍的治疗方法 |
KR20230125339A (ko) | 2016-04-15 | 2023-08-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
KR20190075964A (ko) | 2016-10-13 | 2019-07-01 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
BR112019007210A2 (pt) | 2016-10-20 | 2019-08-13 | Sangamo Therapeutics Inc | métodos e composições para o tratamento da doença de fabry |
AU2017355502B2 (en) * | 2016-11-04 | 2023-08-31 | The Children's Hospital Of Philadelphia | Gene transfer compositions, methods and uses for treating neurodegenerative diseases |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
BR112020005249A2 (pt) | 2017-09-22 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
EP3794131A4 (en) * | 2018-05-15 | 2022-01-26 | University of Massachusetts | RECOMBINANT AAV VECTORS CODING FOR LYSOSOMIAL BETA-GALACTOSIDASE (GLB1) AND CATHEPSIN A |
SG11202100022SA (en) | 2018-07-12 | 2021-01-28 | Rocket Pharmaceuticals Ltd | Gene therapy vectors for treatment of danon disease |
BR112021020421A2 (pt) * | 2019-04-12 | 2021-12-21 | Encoded Therapeutics Inc | Composições e métodos para administração de componentes terapêuticos |
KR20220112283A (ko) | 2019-12-10 | 2022-08-10 | 다케다 야쿠힌 고교 가부시키가이샤 | Hunter 질환 치료용 아데노-연합된 바이러스 벡터 |
CN115379863A (zh) * | 2020-04-14 | 2022-11-22 | 吉尼松公司 | 用于治疗酸性神经酰胺酶缺乏症的载体 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
DE69434594T2 (de) | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | Rekombinante adenoviren-vektor und verfahren zur verwendung |
DK0733103T3 (da) | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Fremstilling af höje titre af rekombinante AAV vektorer |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
EP0755454B1 (en) | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
US6274309B1 (en) | 1996-07-26 | 2001-08-14 | Richard Kolesnick | Method for the modulation of acid-sphingomyelinase-related apoptosis |
US20040076613A1 (en) * | 2000-11-03 | 2004-04-22 | Nicholas Mazarakis | Vector system |
US20050026832A1 (en) * | 1997-11-25 | 2005-02-03 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
US6730297B1 (en) * | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
WO2001036603A2 (en) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
WO2001060377A2 (en) * | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Methods for treatment of lysosomal storage diseases using biphosphonates |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US6667174B2 (en) | 2000-09-18 | 2003-12-23 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
WO2004111198A2 (en) | 2003-06-12 | 2004-12-23 | Genzyme Corporation | Modified human acid sphingomyelinase having increased activity, and methods for making the same |
US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US20060171926A1 (en) * | 2004-04-30 | 2006-08-03 | Passini Marco A | Gene therapy for neurometabolic disorders |
CN104306986A (zh) * | 2005-05-02 | 2015-01-28 | 建新公司 | 神经代谢疾病的基因治疗 |
BRPI0707590A2 (pt) * | 2006-02-08 | 2011-05-10 | Genzyme Corp | terapia gÊnica para a doenÇa de niemann-pick do tipo a |
PL1988823T3 (pl) * | 2006-02-09 | 2019-01-31 | Genzyme Corporation | Powolne dostarczanie dokomorowe |
SI2158322T1 (sl) | 2007-06-06 | 2017-10-30 | Genzyme Corporation | Genska terapija za bolezni lizosomskega shranjevanja |
HRP20211992T1 (hr) | 2009-08-28 | 2022-04-01 | Icahn School Of Medicine At Mount Sinai | Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze |
-
2008
- 2008-06-02 SI SI200831847T patent/SI2158322T1/sl unknown
- 2008-06-02 PL PL17168189T patent/PL3252161T3/pl unknown
- 2008-06-02 PL PL08756596T patent/PL2158322T3/pl unknown
- 2008-06-02 PT PT171681893T patent/PT3252161T/pt unknown
- 2008-06-02 DK DK08756596.6T patent/DK2158322T3/en active
- 2008-06-02 PT PT87565966T patent/PT2158322T/pt unknown
- 2008-06-02 ES ES08756596.6T patent/ES2635726T3/es active Active
- 2008-06-02 EP EP17168189.3A patent/EP3252161B1/en active Active
- 2008-06-02 ES ES17168189T patent/ES2905616T3/es active Active
- 2008-06-02 LT LTEP08756596.6T patent/LT2158322T/lt unknown
- 2008-06-02 EP EP08756596.6A patent/EP2158322B1/en active Active
- 2008-06-02 HU HUE08756596A patent/HUE035779T2/en unknown
- 2008-06-02 WO PCT/US2008/065481 patent/WO2008154198A1/en active Application Filing
- 2008-06-06 AR ARP080102421A patent/AR070000A1/es unknown
-
2009
- 2009-12-04 US US12/631,336 patent/US8796236B2/en active Active
- 2009-12-06 IL IL202522A patent/IL202522A/en active IP Right Grant
-
2014
- 2014-07-10 US US14/328,621 patent/US11369693B2/en active Active
-
2017
- 2017-06-14 IL IL252898A patent/IL252898B/en active IP Right Grant
- 2017-07-31 HR HRP20171165TT patent/HRP20171165T1/hr unknown
- 2017-08-03 CY CY20171100836T patent/CY1119295T1/el unknown
-
2019
- 2019-05-19 IL IL266734A patent/IL266734B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20100173979A1 (en) | 2010-07-08 |
EP2158322A1 (en) | 2010-03-03 |
US11369693B2 (en) | 2022-06-28 |
EP2158322B1 (en) | 2017-05-03 |
EP3252161A1 (en) | 2017-12-06 |
ES2905616T3 (es) | 2022-04-11 |
IL202522A0 (en) | 2011-08-01 |
SI2158322T1 (sl) | 2017-10-30 |
IL252898B (en) | 2019-06-30 |
PL3252161T3 (pl) | 2022-03-07 |
IL202522A (en) | 2017-10-31 |
AR070000A1 (es) | 2010-03-10 |
HRP20171165T1 (hr) | 2017-12-15 |
WO2008154198A1 (en) | 2008-12-18 |
DK2158322T3 (en) | 2017-08-28 |
EP2158322A4 (en) | 2011-06-01 |
PT3252161T (pt) | 2022-02-01 |
LT2158322T (lt) | 2017-08-25 |
ES2635726T3 (es) | 2017-10-04 |
US8796236B2 (en) | 2014-08-05 |
HUE035779T2 (en) | 2018-05-28 |
PT2158322T (pt) | 2017-08-09 |
IL266734B (en) | 2021-10-31 |
US20150151007A1 (en) | 2015-06-04 |
EP3252161B1 (en) | 2021-11-17 |
IL266734A (en) | 2019-07-31 |
IL252898A0 (en) | 2017-08-31 |
PL2158322T3 (pl) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119295T1 (el) | Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης | |
CY1118555T1 (el) | Γονιδιακη θεραπεια για την αμυοτροφικη πλευρικη σκληρυνση και αλλες διαταραχες της σπονδυλικης στηλης | |
CY1118477T1 (el) | Γονιδιακη θεραπεια για τη νωτιαια μυϊκη ατροφια | |
MX2020003965A (es) | Terapias genicas para los trastornos lisosomales. | |
CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
CY1124154T1 (el) | Παραδοση θεραπευτικων παραγοντων στο κνς | |
CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
CY1120096T1 (el) | Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια | |
CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
CY1115617T1 (el) | Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer | |
EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
MX2021004313A (es) | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. | |
EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
CY1115316T1 (el) | Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων | |
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
DE60332355D1 (de) | Hla-a24-restringiertes krebsantigenpeptid | |
EA201171451A1 (ru) | Генетические маркеры, ассоциированные с ответом на интерферон-альфа | |
CY1118843T1 (el) | Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα | |
MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
MX2019004280A (es) | Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina. | |
MY149171A (en) | Treatment and prevention of influenza |